The Medical Letter on Drugs and Therapeutics
Obalon Balloon System - Another Gastric Balloon for Weight Loss
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved the Obalon Balloon System (Obalon), a swallowable intragastric gas-filled balloon device, to facilitate weight loss in adults with a body mass index (BMI) of 30-40 kg/m2 who have not been able to lose weight through diet and exercise. Two other gastric balloon devices, ReShape and Orbera, were approved earlier.1

WEIGHT LOSS PROCEDURES — Surgical treatment of obesity is generally limited to patients with a BMI ≥40 kg/m2, or a BMI ≥35 kg/m2 with an obesity-related comorbidity such as diabetes, hypertension, or hypercholesterolemia. Procedures that cause malabsorption (Roux-en-Y gastric bypass and bilio-pancreatic diversion) lead to greater weight loss, but also have more adverse effects than purely restrictive procedures such as adjustable gastric banding or sleeve gastrectomy. ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Obalon Balloon System - Another Gastric Balloon for Weight Loss
Article code: 1523d
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian